# TNBC-MERIT (NCT02316457)

> RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02316457
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: BioNTech SE
- Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Interventions: IVAC_W_bre1_uID; IVAC_W_bre1_uID/IVAC_M_uID
- Enrollment: 42
- Primary outcome: Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID
- Primary outcome: Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID plus IVAC_M_uID

## Indexed commentary on TNBC-MERIT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tnbc-merit-nct02316457